Brought to you by 
Lilly sells manufacturing site to Covance, signs R&D contract
11 Aug 2008
Executive Summary
Eli Lilly announced that it has sold to CRO Covance its 450-acre preclinical drug development facility in Greenfield, Indiana for $50mm up front. The companies have also entered into an agreement where Covance will provide Lilly with various drug development services over the next ten years, a partnership valued at about $1.6bn.
Deal Industry
- Contract Research, Toxicology Testing-CRO
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lilly sells manufacturing site to Covance, signs R&D contract
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice